In addition, we tested the diagnostic efficacy with our newly developed motor dysfunction questionnaire (MDQ) (Table A1) which has been validated with dopamine transporter imaging by comparing motor dysfunctions among DLB, AD, and ND groups (Chiu et al., 2021). This evidence concerns the gene SLC6A3 and Alzheimer disease.